Key Takeaways:
- In the food industry, certified validation schemes allow laboratories to verify alternative methods rather than repeating a full validation from scratch.
- A similar approach in pharmaceutical microbiology could reduce validation efforts, increase confidence in Rapid Microbiological Methods (RMMs), and accelerate their adoption without compromising scientific rigor.
In a previous article, we tried to explain why rapid and alternative methods are still rarely used routinely in pharmaceutical microbiology laboratories.
One of the main barriers is validation.
Today, any laboratory wishing to implement a rapid method generally has to perform a full or near-full validation under its own conditions.
From a regulatory and scientific perspective, this makes sense.
However, it is also time-consuming, costly, and often discouraging… which helps explain why so few Rapid Microbiological Methods (RMMs) are used routinely.
This leads us to an important question:
Could a different model be possible?
Validation of Alternative Methods in the Food Industry
Unlike in the pharmaceutical industry, in the food industry, alternative microbiological methods are widely used for routine testing.
Why?
Because there is a more structured validation and certification framework than in the pharmaceutical industry.
A supplier can choose to have its alternative method validated and certified.
To do so, the supplier works with an independent expert laboratory.
This expert laboratory performs a full validation study, comparing the alternative method with the corresponding ISO reference method. The validation protocol itself is defined in a standard: ISO 16140-2.
The validation data are then submitted to a certification body such as AFNOR Certification, MicroVal, or AOAC.
If the results are considered satisfactory, the method is certified for a specific scope of application.
This does not mean that end users have nothing left to do. However, they do not need to repeat the entire validation process from scratch.
Instead, they perform a verification study under their own conditions, using their own matrices, strains, constraints, and laboratory environment. The protocol for this verification is described in ISO 16140-3.
And that changes everything.
Why Not Imagine a Similar Model for Pharma?
The question we keep asking ourself is simple: why not take inspiration from this model for pharmaceutical microbiology?
One could imagine a rapid technology being evaluated by an independent expert laboratory using a standardized and widely recognized protocol.
This expert laboratory would perform a large part of the validation work, including analytical performance, comparison with the compendial method, robustness, inclusivity, exclusivity, limits of detection and quantification, reproducibility, and perhaps even an interlaboratory study.
At the end of this evaluation, the method could receive some form of certification for a specific application.
The end user would then only need to perform a verification study within their own laboratory, focused on their products, their environmental isolates, and their specific operating conditions.
In many ways, this verification could be viewed as a comparability protocol rather than a full validation from scratch.
What Benefits Could This Bring for RMM Adoption in Pharma?
Such a model could offer several advantages.
First, it would prevent every laboratory from repeating exactly the same validation work independently.
Second, it would allow much of the validation effort to be carried out by specialized teams with extensive experience in this type of study.
It could also increase user confidence: if a method has been successfully evaluated by an expert laboratory, there is every reason to believe it can perform well elsewhere under similar conditions.
In addition, it could simplify discussions with regulatory authorities, auditors, and quality teams.
In short, such a certification approach could accelerate the adoption of Rapid Microbiological Methods (RMMs) while maintaining a very high level of scientific and regulatory rigor.
Conclusion
If we truly want to accelerate the adoption of rapid methods in pharmaceutical microbiology, we will probably need to act on several fronts: training, supplier support, user requirements, statistical analysis, and regulatory dialogue.
But we may also need to rethink part of the validation model itself.
For many years, the food industry has relied on a certification system for alternative methods that allows laboratories to start with a solid validation package and then perform a verification study tailored to their own conditions.
Could the pharmaceutical industry take inspiration from this approach?
We don’t have the answer… But we do believe the question is worth discussing. What do you think?
Note: An initiative is currently underway within the EDQM (European Directorate for the Quality of Medicines & HealthCare). A working group is reportedly being formed. Based on our understanding, the objective would be to establish a form of certification for primary validation studies. This is an excellent initiative that could significantly reduce the time and effort required to validate alternative microbiological methods. The question now is: when will it become a reality?